Medical devices, healthcare technology and the business of care
PMA approval · P170030

ORSIRO Sirolimus Eluting Coronary Stent System

Biotronik AG · Decision date Feb 22, 2019

MEDTECHLEDGER EXPLANATIONP170030

What did the FDA approve?

FDA approved the Orsiro Sirolimus Eluting Coronary Stent System from Biotronik AG on February 22, 2019. The approval record states the device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction, or documented silent ischemia due to atherosclerotic lesions in native coronary arteries.

The stated indication includes patients with diabetes mellitus and specifies a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of less than 36 mm. The record does not contain a supplement type or supplement reason, and no clinical effectiveness data or trial information is provided in the source fields.

FDA approval order statement

Approval of the Orsiro Sirolimus Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of < 36 mm.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Feb 22, 2019

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170030
Regulatory pathway
Premarket approval application
Applicant
Biotronik AG
Product code
NIQ
Decision code
APPR
Decision date
Feb 22, 2019
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Applicant
Biotronik AG
Product code
NIQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P170030 received

    Application receipt date recorded by FDA.

  2. P170030 · FDA decision

    APPR

  3. P170030/S066 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170030

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records